Ischemix Overview
- Founded
- 1999
- Status
- Private
- Employees
- 8
- Latest Deal Type
- Angel
- Latest Deal Amount
- $6.6M
Ischemix General Information
Description
Developer of drugs to defend the body's cells against ischemia-reperfusion injury. The company develops a portfolio of therapeutic compounds for the prevention and treatment of serious cardio-renal conditions.
Contact Information
Website
www.ischemix.com
Formerly Known As
CereMedix
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- 63 Great Road
- Maynard, MA 01754
- United States
+1 (978) 000-0000
Ischemix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 05-Jun-2014 | $6.6M | 000.00 | Completed | Generating Revenue | |
| 1. Early Stage VC | 0000 | 0000 | Completed | Startup |
Ischemix Executive Team (7)
Ischemix Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Edward Shashoua Ph.D | Self | Board Member | 000 0000 |
| John Norris JD | Self | Board Member | 000 0000 |
| Reinier Beeuwkes Ph.D | Ischemix | Chairman & Chief Scientific Officer | 000 0000 |
Ischemix Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial